Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Current Leases (2021 - 2025)

Verrica Pharmaceuticals has reported Current Leases over the past 5 years, most recently at $405000.0 for Q4 2025.

  • Quarterly results put Current Leases at $405000.0 for Q4 2025, up 15.06% from a year ago — trailing twelve months through Dec 2025 was $405000.0 (up 15.06% YoY), and the annual figure for FY2025 was $405000.0, up 15.06%.
  • Current Leases for Q4 2025 was $405000.0 at Verrica Pharmaceuticals, up from $366000.0 in the prior quarter.
  • Over the last five years, Current Leases for VRCA hit a ceiling of $846000.0 in Q3 2024 and a floor of $6000.0 in Q3 2021.
  • Median Current Leases over the past 5 years was $313500.0 (2023), compared with a mean of $327000.0.
  • Biggest five-year swings in Current Leases: soared 2629.03% in 2024 and later plummeted 56.74% in 2025.
  • Verrica Pharmaceuticals' Current Leases stood at $245000.0 in 2021, then increased by 15.51% to $283000.0 in 2022, then surged by 32.86% to $376000.0 in 2023, then dropped by 6.38% to $352000.0 in 2024, then increased by 15.06% to $405000.0 in 2025.
  • The last three reported values for Current Leases were $405000.0 (Q4 2025), $366000.0 (Q3 2025), and $318000.0 (Q2 2025) per Business Quant data.